B. Riley Forecasts Higher Earnings for Eton Pharmaceuticals

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - B. Riley increased their Q2 2025 EPS estimates for shares of Eton Pharmaceuticals in a note issued to investors on Wednesday, June 4th. B. Riley analyst M. El-Saadi now expects that the company will earn ($0.04) per share for the quarter, up from their prior estimate of ($0.06). B. Riley currently has a "Buy" rating and a $26.00 target price on the stock. The consensus estimate for Eton Pharmaceuticals' current full-year earnings is ($0.14) per share. B. Riley also issued estimates for Eton Pharmaceuticals' Q3 2025 earnings at $0.15 EPS, Q4 2025 earnings at $0.52 EPS, FY2025 earnings at $0.58 EPS, FY2026 earnings at $1.13 EPS and FY2027 earnings at $1.83 EPS.

Other equities analysts have also issued reports about the stock. Craig Hallum increased their price objective on shares of Eton Pharmaceuticals from $26.00 to $28.00 and gave the company a "buy" rating in a research report on Wednesday, May 14th. HC Wainwright reissued a "buy" rating and issued a $35.00 price target (up from $33.00) on shares of Eton Pharmaceuticals in a report on Thursday, May 29th.

Eton Pharmaceuticals Trading Down 2.4%

ETON opened at $16.84 on Monday. Eton Pharmaceuticals has a 1-year low of $3.18 and a 1-year high of $21.48. The stock's fifty day simple moving average is $16.24 and its 200 day simple moving average is $14.95. The stock has a market cap of $451.62 million, a PE ratio of -76.55 and a beta of 1.28.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.02). The business had revenue of $17.28 million during the quarter, compared to the consensus estimate of $14.33 million. Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in ETON. AlphaQuest LLC bought a new position in shares of Eton Pharmaceuticals in the first quarter worth $53,000. Tower Research Capital LLC TRC bought a new position in Eton Pharmaceuticals in the 4th quarter valued at about $86,000. Quantbot Technologies LP bought a new position in Eton Pharmaceuticals in the 1st quarter valued at about $101,000. Jefferies Financial Group Inc. bought a new position in Eton Pharmaceuticals in the 4th quarter valued at about $133,000. Finally, Point72 Asia Singapore Pte. Ltd. increased its holdings in Eton Pharmaceuticals by 18.3% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 10,561 shares of the company's stock valued at $141,000 after buying an additional 1,634 shares during the period. 27.86% of the stock is owned by institutional investors.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.